MedPath

Goal Directed Fluid Therapy and Postoperative Ileus

Not Applicable
Completed
Conditions
Postoperative Ileus
Registration Number
NCT01818375
Lead Sponsor
Gabriele Baldini, MD, MSc, Assistant Professor
Brief Summary

Despite Goal Directed Fluid Therapy (GDFT) has shown a reduction of hospitalization and overall complications in patients undergoing abdominal surgery, there is a need to address the effect of implementing GDFT on the incidence of specific surgical complications and in a context of en enhanced recovery program (ERP). Specifically, studies investigating the impact of GDFT on primary postoperative ileus (POI) in patients undergoing laparoscopic colorectal surgery and using an ERP are missing.

It is hypothesized that the incidence of primary POI will be reduced in patients receiving intraoperative GDFT compared to patients receiving Standard Fluid Therapy (SFT) after elective laparoscopic colorectal surgeries with an ERP program.

Detailed Description

Randomized Controlled Trial. Study population: elective laparoscopic colorectal resections with an Enhanced Recovery Program (ERP) Sample size: 128 patients (140 accounting for drops out)

Two arms:

GDFT: patients will receive GDFT esophageal doppler guided; SFT: patients will receive SFT based on standard anesthesia formula and international guidelines to calculate fluid requirements.

Study Hypothesis: the incidence of primary POI will be reduced in patients receiving intraoperative GDFT compared to patients receiving SFT after elective laparoscopic colorectal surgeries with an ERP program.

ERP: all patients will receive the same perioperative care according to the Enhanced Recovery After Surgery ERAS® program guidelines. Intravenous fluid will be stopped the first day after surgery. Patients will be allowed to have clear fluids the same day of surgery and diet, as tolerated, the first day after surgery.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
128
Inclusion Criteria
  • All patients undergoing elective laparoscopic colorectal resection with an Enhanced Recovery Program
Exclusion Criteria
  1. Age <18 yr

  2. Emergency surgery

  3. Patients who do not understand, read or communicate in either French or English

  4. Patients who had undergone esophageal or gastric surgery

  5. Esophageal pathology (esophageal varices or cancer)

  6. Patients with coarctation of the aorta or aortic stenosis

  7. Chronic atrial fibrillation

  8. Preoperative bowel obstruction 8. Coagulopathies 9. Chronic use of opioids

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Primary postoperative ileus (POI)participants will be followed for the duration of hospital stay, an expected average of 3 days

Patients will be considered having primary POI if at least one symptom, for each of the following criteria, will be reported:

i. vomiting (+/- nausea) OR abdominal distension AND ii. Absence of passing gas/stool OR not tolerating oral diet.

Secondary Outcome Measures
NameTimeMethod
Intraoperative hemodynamic measurementsParticipants will be followed for the duration of hospital stay, an expected average of 3 days

Systolic blood pressure; diastolic blood pressure; mean arterial blood pressure; heart rate; flow-time corrected (FTc); stroke distance (SD); Peak velocity (PV); stroke volume (SV); stroke index (SVI); cardiac output (CO); cardiac Index (CI)

Intraoperative and postoperative fluids and blood products requiredParticipants will be followed for the duration of hospital stay, an expected average of 3 days
Vasoactive agents requiredParticipants will be followed for the duration of hospital stay, an expected average of 3 days
Urinary outputParticipants will be followed for the duration of hospital stay, an expected average of 3 days
Intraoperative and postoperative urinary outputParticipants will be followed for the duration of hospital stay, an expected average of 3 days
Intraoperative and Postoperative opioid consumptionParticipants will be followed for the duration of hospital stay, an expected average of 3 days

Intraoperative opioid administration and postoperative opioid consumption

Postoperative nausea and vomiting (PONV)Participants will be followed for the duration of hospital stay, an expected average of 3 days
Time spent out of bedParticipants will be followed for the duration of hospital stay, an expected average of 3 days
Postoperative complications (Clavien Classification)Participants will be followed for the duration of hospital stay, an expected average of 3 days
Patients' weightParticipants will be followed for the duration of hospital stay, an expected average of 3 days
Quality of surgical recovery scoreParticipants will be followed for the duration of hospital stay, an expected average of 3 days
Readiness to be dischargedParticipants will be followed for the duration of hospital stay, an expected average of 3 days

: according to the colorectal pathway, hospital discharge is planned on postoperative day 3. Patients will be discharged if afebrile, able to tolerate oral diet, pain is controlled (NRS \< 4), and able to ambulate

Length of hospital stayParticipants will be followed for the duration of hospital stay, an expected average of 3 days

Trial Locations

Locations (1)

Montreal General Hospital

🇨🇦

Montreal, Quebec, Canada

Montreal General Hospital
🇨🇦Montreal, Quebec, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.